Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Inovalis Real Estate Investment Trust (INO) Share Price
Media headlines about Inovalis Real Estate Investment Trust (NASDAQ:INO) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inovalis Real Estate Investment Trust earned a news impact score of 0.09 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.9999281018903 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Inovio Pharmaceuticals to Participate In Upcoming Investment Conferences (finance.yahoo.com)
- What You Need to Know From Inovio Pharmaceuticals' Q3 Update (finance.yahoo.com)
- Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss (finance.yahoo.com)
- Inovio Pharmaceuticals, Inc. (INO) Downgraded by ValuEngine to “Strong Sell” (americanbankingnews.com)
- EARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q3 Earnings Report (rttnews.com)
A number of equities research analysts have recently weighed in on INO shares. Aegis reaffirmed a “buy” rating and set a $14.00 price target on shares of Inovalis Real Estate Investment Trust in a research note on Tuesday, July 18th. HC Wainwright set a $13.00 price target on Inovalis Real Estate Investment Trust and gave the stock a “buy” rating in a research note on Thursday, July 27th. BidaskClub downgraded Inovalis Real Estate Investment Trust from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Maxim Group set a $12.00 price target on Inovalis Real Estate Investment Trust and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Finally, ValuEngine raised Inovalis Real Estate Investment Trust from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of C$19.16.
Inovalis Real Estate Investment Trust (NASDAQ INO) traded up C$0.31 on Friday, reaching C$4.74. The company’s stock had a trading volume of 1,970,000 shares, compared to its average volume of 1,180,000. Inovalis Real Estate Investment Trust has a 12-month low of C$4.40 and a 12-month high of C$9.86.
Inovalis Real Estate Investment Trust (NASDAQ:INO) last released its earnings results on Wednesday, November 8th. The company reported C($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of C($0.25) by C($0.15). Inovalis Real Estate Investment Trust had a negative net margin of 46.44% and a negative return on equity of 33.16%. The business had revenue of C$2.60 million during the quarter, compared to analyst estimates of C$10.27 million. During the same period last year, the business earned ($0.28) EPS. The business’s quarterly revenue was down 79.2% compared to the same quarter last year.
The company also recently disclosed a monthly dividend, which was paid on Monday, October 16th. Stockholders of record on Friday, September 29th were issued a dividend of $0.069 per share. This represents a $0.83 annualized dividend and a dividend yield of 17.47%. The ex-dividend date was Thursday, September 28th.
WARNING: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-inovalis-real-estate-investment-trust-ino-share-price/1696746.html.
About Inovalis Real Estate Investment Trust
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with Analyst Ratings Network's FREE daily email newsletter.